A Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients With Leptomeningeal Metastases With or Without Parenchymal Brain Involvement.

Trial Profile

A Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients With Leptomeningeal Metastases With or Without Parenchymal Brain Involvement.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Cytarabine (Primary) ; Methotrexate (Primary)
  • Indications Breast cancer; Cancer metastases
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Apr 2012 Additional trial centers identified as reported by ClinicalTrials.gov.
    • 23 Mar 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 21 Oct 2011 Additional lead trial center (National Cancer Institute) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top